CL2024002124A1 - Formas sólidas cristalinas de inhibidores de la helicasa-primasa y proceso de preparación de las mismas - Google Patents

Formas sólidas cristalinas de inhibidores de la helicasa-primasa y proceso de preparación de las mismas

Info

Publication number
CL2024002124A1
CL2024002124A1 CL2024002124A CL2024002124A CL2024002124A1 CL 2024002124 A1 CL2024002124 A1 CL 2024002124A1 CL 2024002124 A CL2024002124 A CL 2024002124A CL 2024002124 A CL2024002124 A CL 2024002124A CL 2024002124 A1 CL2024002124 A1 CL 2024002124A1
Authority
CL
Chile
Prior art keywords
helicase
crystalline forms
solid crystalline
preparation process
primase inhibitors
Prior art date
Application number
CL2024002124A
Other languages
English (en)
Spanish (es)
Inventor
Kleymann Gerald
Gege Christian
Original Assignee
Innovative Molecules Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innovative Molecules Gmbh filed Critical Innovative Molecules Gmbh
Publication of CL2024002124A1 publication Critical patent/CL2024002124A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/54—Nitrogen and either oxygen or sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CL2024002124A 2022-01-17 2024-07-15 Formas sólidas cristalinas de inhibidores de la helicasa-primasa y proceso de preparación de las mismas CL2024002124A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP22151820 2022-01-17
EP22170332 2022-04-27

Publications (1)

Publication Number Publication Date
CL2024002124A1 true CL2024002124A1 (es) 2024-11-22

Family

ID=84982261

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2024002124A CL2024002124A1 (es) 2022-01-17 2024-07-15 Formas sólidas cristalinas de inhibidores de la helicasa-primasa y proceso de preparación de las mismas

Country Status (12)

Country Link
US (1) US20250115565A1 (cg-RX-API-DMAC10.html)
EP (1) EP4466255A1 (cg-RX-API-DMAC10.html)
JP (1) JP2025502300A (cg-RX-API-DMAC10.html)
KR (1) KR20240134979A (cg-RX-API-DMAC10.html)
AU (1) AU2023206628A1 (cg-RX-API-DMAC10.html)
CA (1) CA3246779A1 (cg-RX-API-DMAC10.html)
CL (1) CL2024002124A1 (cg-RX-API-DMAC10.html)
IL (1) IL314188A (cg-RX-API-DMAC10.html)
MX (1) MX2024008821A (cg-RX-API-DMAC10.html)
PY (1) PY2302301A (cg-RX-API-DMAC10.html)
UY (1) UY40111A (cg-RX-API-DMAC10.html)
WO (1) WO2023135303A1 (cg-RX-API-DMAC10.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4580601A1 (en) * 2022-08-29 2025-07-09 Assembly Biosciences, Inc. Pharmaceutical compositions for herpes virus
IL325911A (en) 2023-07-17 2026-03-01 Innovative Molecules Gmbh Micronized crystalline hydrochloride salts of antiviral helicase-primase inhibitor compounds
WO2026078039A1 (en) 2024-10-09 2026-04-16 Innovative Molecules Gmbh Oral administration forms of antiviral helicase-primase inhibitors

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DOP2000000109A (es) 1999-12-23 2002-08-30 Gerald Kleymann Derivados de tiazolilamida
DE10131128A1 (de) 2001-06-28 2003-01-16 Bayer Ag Sekundäre Sulfonamide
PH12018501979B1 (en) 2016-04-06 2023-05-05 Innovative Molecules Gmbh Aminothiazole derivatives useful as antiviral agents
PL3692039T3 (pl) 2017-10-05 2023-04-17 Innovative Molecules Gmbh Enancjomery podstawionych tiazoli jako związki przeciwwirusowe
TW202038947A (zh) 2018-11-28 2020-11-01 德商創新分子有限責任公司 在與溶瘤病毒之組合療法中治療癌症的解旋酶引子酶抑制劑
AU2021367976A1 (en) 2020-10-29 2023-06-08 Innovative Molecules Gmbh Deuterated aminothiazole compounds as antiviral compounds

Also Published As

Publication number Publication date
IL314188A (en) 2024-09-01
UY40111A (es) 2023-08-15
PY2302301A (es) 2023-10-31
US20250115565A1 (en) 2025-04-10
WO2023135303A1 (en) 2023-07-20
CA3246779A1 (en) 2023-07-20
TW202337444A (zh) 2023-10-01
EP4466255A1 (en) 2024-11-27
MX2024008821A (es) 2024-07-29
KR20240134979A (ko) 2024-09-10
AU2023206628A1 (en) 2024-08-01
JP2025502300A (ja) 2025-01-24

Similar Documents

Publication Publication Date Title
UY40111A (es) Formas cristalinas sólidas de inhibidores de helicasa-primasa y proceso de preparación de las mismas
CL2024001022A1 (es) Moléculas pequeñas para el tratamiento del cáncer
CR20210608A (es) Pirroles tricíclicos condensados como moduladores de alfa-1 antitripsina
CO2020015758A2 (es) Compuestos de purinona y su uso en el tratamiento del cáncer
CO2021004679A2 (es) Inhibidores de la replicación del virus de la inmunodeficiencia humana
ECSP20022130A (es) Nucleósidos sustituidos, nucleótidos y análogos de estos
CO2019011873A2 (es) Compuestos de heteroarilo bicíclicos 6–6 fusionados y su uso como inhibidores de lats
DOP2019000168A (es) Compuestos de amino-triazolopiridina y su uso en el tratamiento del cáncer
MX2022009596A (es) Anticuerpos anti-ror1 y composiciones.
CL2023002362A1 (es) Derivados de tetrahidroazepina bicíclicos para el tratamiento del cáncer
MX2021015935A (es) Formas de sal de acido bempedoico y metodos para utilizar el mismo.
CR20180092A (es) Compuestos antivirales de fosfodiamida de éster de beta-aminoácido
DOP2016000308A (es) Compuestos de 1, 3, 4-tiadiazol y uso de los mismos para el tratamiento del cáncer
CL2023002223A1 (es) Inhibidores de cdk2 y métodos de uso de los mismos
MX2024004119A (es) Composiciones y metodos para el tratamiento de enfermedades de repeticion cag
CL2022003703A1 (es) Compuestos antibióticos, métodos de fabricación de los mismos, composiciones farmacéuticas conteniendo los mismos y usos
CO2019011546A2 (es) Compuestos y métodos para el tratamiento de enfermedades parasitarias
DOP2026000079A (es) Inhibidores del factor b del complemento y usos de los mismos
CO2025003090A2 (es) Compuestos de piridinona sustituida como inhibidores de cbl-b
MX2024002886A (es) Metodos para tratar enfermedades neurodegenerativas.
CU24699B1 (es) Composiciones para tratar y/o prevenir la infección por el virus de la hepatitis b
MX2026000476A (es) Sales clorhidrato cristalinas micronizadas de compuestos inhibidores antiviricos de la helicasa-primasa
CO2025015894A2 (es) Inhibidores de ciclina
CL2025000078A1 (es) Formas sólidas de un derivado de triazina como modulador cbl-b
CL2024003167A1 (es) Proteínas cd24 mutantes y usos de las mismas para la profilaxis y el tratamiento del cáncer